Characteristics N=20 (%)
Gender- Male / Female: no. (%) 7(35) / 13(65)
Age: Mean (years) ± SD 55 ± 17
Time since PAH diagnosis - yr 4 ± 4
PAH classification
IPAH 12 (60)
CTD-PAH 6 (30)
Group 5 PH (Sarcoid) 1 (5)
Mixed disease 1 (5)
WHO functional class – no. (%)
I 0
II 10 (50)
III 10 (50)
IV 0
6-Minute walk distance* – Mean (meters) ± SD 331 ± 165
Risk stratification
Low risk 5 (25)
Intermediate risk 13 (65)
High risk 2 (10)
Baseline medications for PAH – no. (%)
ERA+ PD5 inhibitors 17 (85)
ERA + sGC stimulator 1 (5)
ERA+ PD5 inhibitors + PGI2 therapy 2 (10)
Baseline medications (excluding targeted PAH med.) – no. (%)
None 1 (5)
1-2 10 (50)
3-6 7 (35)
>7 2 (10)
Co-morbidities
None 3 (15)
Respiratory 11 (55)
Cardiovascular 4 (20)
Gastrointestinal 4 (20)